Increased incidence of cancer in end-stage renal disease: Potential pathogenetic mechanisms;Erhohte Krebsinzidenz bei terminaler Niereninsuffizienz: Potentielle pathogenetische Mechanismen

Schweizerische Medizinische Wochenschrift

Volumn 127, Issue 14, 1997, Pages 597-604

  Vamvakas, S ^a   Bahner, U ^b   Heidland, A ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Kuratorium für Dialyse und Nierentransplantation   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGENESIS; CARCINOGENIC ACTIVITY; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; KIDNEY CANCER; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY INFECTION; MALIGNANT TRANSFORMATION; REVIEW; CELL TRANSFORMATION; CHRONIC KIDNEY FAILURE; DNA REPAIR; DRUG EFFECT; IMMUNITY; IMMUNOLOGY; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIOXIDANT; CARCINOGEN; IMMUNOSUPPRESSIVE AGENT;

ANTIOXIDANTS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DNA REPAIR; HUMANS; IMMUNITY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; NEOPLASMS;

EID: 0031553880     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS: Increased incidence of malignancy during chronic renal failure. Lancet 1975/I: 883-886.
2. Giacchino F, Formica M, Quarello F, Bonello F, Piccoli G: High incidence of cancer in uremic patients. Clin Nephrol 1983; 22: 265-266.
3. Inamoto H, Ozaki R, Matsuzaki T, Wakui M, Saruta T, Osawa A: Incidence and mortality patterns of malignancy and factors affecting the risk of malignancy in dialysis patients. Nephron 1991; 59: 611-617.
4. Iseki K, Osawa A, Fukiyama K: Evidence for increased cancer deaths in chronic dialysis patients. Am J Kidney Dis 1993; 22: 308-313.
5. Marple JT, MacDougall M: Development of malignancy in the end-stage renal disease patient. Semin Nephrol 1993; 13: 306-314.
6. Port FK, Ragheb NE, Schwartz AG, Hawthorne VM: Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis 1989; 14: 119-123.
7. Ishikawa I, Saito Y, Shikura N, Kitada H, Shinoda A, Suzuki S: Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis 1990; 16: 452-458.
8. Levine E: Renal cell carcinoma in uremic acquired renal cystic disease: incidence, detection, and management. Urol Radiol 1992; 13: 203-210.
9. Dunnill MS, Millard PR, Oliver D: Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance hemodialysis. J Clin Pathol 1977; 30: 868-877.
10. Mickisch O, Bommer J, Bachmann S, Waldherr R, Mann JFE, Ritz E: Multicystic transformation of kidneys in chronic renal failure. Nephron 1984; 38: 93-99.
11. Noronha IL, Ritz E, Waldherr R, Stein G, Fassbinder W: Renal cell carcinoma in dialysis patients with acquired renal cysts. Nephrol Dial Transplant 1989; 4: 763-769.
12. Grantham JJ: Fluid selection, cellular proliferation, and the pathogenesis of renal epithelial cysts. J Am Soc Nephrol 1993; 3: 1843-1857.
13. Marple JT, MacDougall M, Chonko AM: Renal cancer complicating acquired cystic kidney disease [see comments]. J Am Soc Nephrol 1994; 4: 1951-1956.
14. Roberts PF: Bilateral renal carcinoma associated with polycystic kidneys. Br Med J 1973; 3: 273-274.
15. Grantham JJ: Polycystic kidney disease: neoplasia in disguise. Am J Kidney Dis 1990; 15: 110-116.
16. Neumann HP, Lips CJ, Hsia YE, Zbar B: Von Hippel-Lindau syndrome. Brain Pathol 1995; 5: 181-193.
17. Bengtsson U, Anerwall L, Ekman L, Lehmann L: Transitional cell tumors of the renal pelvis in analgetic abusers. Scand J Urol Nephrol 1968; 2: 145-150.
18. Lornoy W, Becaus I, Morell V: A new complication in analgesic nephropathy: the development of a renal cell carcinoma. Kidney Int 1986; 30: 641-647.
19. Pecqueux JC, Schwarz A, Dieckmann KP, Offermann G: Cancer incidence in patients on chronic dialysis and in renal transplant recipients. Urol Int 1990; 45: 290-292.
20. Thon WF, Kliem V, Truss MC, Anton P, Kuczyk M et al.: Denovo urothelial carcinoma of the upper and lower urinary tract in kidney-transplant patients with end-stage analgesic nephropathy. World J Urol 1995;13: 254-261.
21. Sattler TA, Dimitrov T: Relation between Balkan nephropathy and urinary tract tumors. Lancet 1977/I: 278-280.
22. Radovanovic Z, Jankovic S, Jevremovic I: Incidence of tumors of urinary organs in a focus of Balkan endemic nephropathy. Kidney Int 1991; 34: S75-S76.
23. IARC-Scientific-Publications: Mycoroxins, endemic nephropathy and urinary tract tumours. International Agency for Research on Cancer, Lyon, 1991.
24. Penn I: The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101-1103.
25. Penn I: Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am 1993; 7: 431-445.
26. Duckett T, Belldegrun A: Immunology in cancer. Curr Opin Oncol 1992; 4: 149-155.
27. Aboulafia DM: Human immunodeficiency virus-associated neoplasms: epidemiology, pathogenesis, and review of current therapy. Cancer Pract 1994; 2: 297-306.
28. Goldblum SE, Reed WP: Host defences and immunologic alterations associated with chronic hemodialysis. Ann Intern Med 1980; 93: 579-613.
29. Schollmeyer P, Bozkurt F: The immune system of the uremic patient: hemodialysis vs CAPD. Clin Nephrol 1988; 30: (Suppl.): 37-40.
30. Alexiewicz JM, Gaciong Z, Klinger M, Linker-Israeli M, Pitts TO, Massry SG: Evidence of impaired T cell function in hemodialysis patients: potential role for secondary hyperparathyroidism. Am J Nephrol 1990; 10: 495-501.
31. Kohler H, Girndt M, Dumann H, Klingel R: The immune defect in kidney failure. I. The clinical manifestations. Dtsch Med Wochenschr 1993; 118: 757-761.
32. Kohler H, Girndt M, Dumann H, Klingel R: The immune defect in kidney failure. II. The mechanisms of the "uremic" immune defect. Dtsch Med Wochenschr 1993; 118: 790-795.
33. Hoy WE, Cestero RV, Freeman RB: Deficiency of B and T lymphocytes in uremic subjects and partial improvement with maintenance hemodialysis. Nephron 1978; 20: 182-188.
34. Köhler H, Arnold W, Renschin G, Dormeyer HH, Meyer zum Buschenfelde KH: Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984; 25: 124-128.
35. Chatenoud L, Herbelin A, Beaurain G, Descamps-Latscha, B: Immune deficiency of the uremic patient. Adv Nephrol Necker Hosp 1990; 19: 259-274.
36. Gibbons RA, Martinez OM, Garovoy MR: Altered monocyte function in uremia. Clin Immunol Immunopathol 1990; 56: 66-80.
37. Donati D, Degiannis D, Homer L, Gastaldi L, Raskova J, Raska K Jr: Immune deficiency in uremia: interleukin-2 production and responsiveness and interleukin-2 receptor expression and release. Nephron 1991; 58: 268-275.
38. Massry SG, Alexiewicz JM, Gaciong Z, Klinger M: Secondary hyperparathyroidism and the immune system in chronic renal failure. Semin Oncol 1991; 11: 186-201.
39. Descamps-Latscha B, Chatenoud L: T cells and B cells in chronic renal failure. Semin Nephrol 1996; 16: 183-191.
40. Gerez L, Madar L, Shkolnik T, Kristal B, Arad G et al.: Regulation of interleukin-2 and interferon-gamma gene expression in renal failure. Kidney Int 1991; 40: 266-272.
41. Ames BN, Shigenaga MK, Hagen T: Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90: 1915-1922.
42. Avissar N, Ornt DB, Yagil Y, Horowitz S, Watkins RH et al.: Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol 1994; 266: C367-C375.
43. Yoshimura S, Suemizu H, Nomoto Y, Sakai H, Katsuoka Y et al.: Plasma glutathione peroxidase deficiency caused by renal dysfunction. Nephron 1996; 73: 207-211.
44. Kallistratos G, Evangelou A, Seferiadi K, Vezyraki P, Barboutis K: Selenium and hemodialysis: serum selenium levels in healthy persons, non-cancer and cancer patients with chronic renal failure. Nephron 1985; 41: 217-222.
45. Bonomini M, Albertazzi A: Selenium in uremia. Artif Organs 1995; 19: 443-448.
46. Bonomini M, Forster S, De-Risio F, Rychly J, Nebe B et al.: Effects of selenium supplementation on immune parameters in chronic uremic patients on hemodialysis. Nephrol Dial Transplant 1995; 10: 1654-1661.
47. Lange JH: Reanalysis of epidemiological data for selenium anti-cancer activity. Toxicol Ind Health 1991; 7: 319-325.
48. Griffin AC: Role of selenium in the chemoprevention of cancer. Adv Cancer Res 1979; 29: 419-422.
49. Willet WC, Morris JS, Pressel S, Taylor JO, Polk BE et al.: Prediagnostic serum selenium and risk of cancer. Lancet 1983/I: 130-134.
50. Yu SY, Zhu YJ, Li WG, Huang QS, Huang CZ et al.: A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res 1991; 29: 289-294.
51. Ip C, Ganther HE: Comparison of selenium and sulfur analogs in cancer prevention. Carcinogenesis 1992; 13: 1167-1170.
52. Mimic-Oka J, Simic T, Ekmescic V, Dragicevic P: Erythrocyte glutathione peroxidase and superoxide dismutase activities in different stages of chronic renal failure. Clin Nephrol 1995; 44: 44-48.
53. Stein G, Schön S, Sperschneider H, Richter R, Fünfstück R, Günther K: Vitamin status in patients with chronic renal failure. Contrib Nephrol 1988; 65: 33-36.
54. Block G, Patterson B, Subar A: Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992; 18: 1-29.
55. Gilmour ER, Hartley GH, Goodship THJ: Trace elements and vitamins in renal disease. In: Klahr WE, M, S (Hrsg): Nutrition and the Kidney. Little, Brown and Company, 1993: 114-131.
56. Triolo L, Lippa S, Oradei A, De-Sole P, Mori R: Serum coenzyme Q10 in uremic patients on chronic hemodialysis. Nephron 1994; 66: 153-156.
57. Tavani A, Lavecchia C: Fruit and vegetable consumption and cancer risk in a Mediterranean population. Am J Clin Nutr 1995; 61: S1374-S1377.
58. Roselaar SE, Nazhat NB, Winyard PG, Jones P, Cunningham J, Blake DR: Detection of uremic plasma by electron spin resonance spectroscopy. Kidney Int 1995; 48: 199-206.
59. Cohen SM, Ellwein LB: Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 1991; 51: 6493-6505.
60. Cohen SM: Role of cell proliferation in regenerative and neoplastic disease. Toxicol Lett 1995; 82/83: 15-21.
61. Colombo M, de-Franchis R, Del-Ninno E, Sangiovanni A, De-Fazio C et al.: Hepatocellular carcinoma in Italian patients with cirrhosis [see comments]. N Engl J Med 1991; 325: 675-680.
62. Fabrizi F, Lunghi G, Guarnori I, Raffaele L, Crepaldi M et al.: Incidence of seroconversion for hepatitis C virus in chronic hemodialysis patients: a prospective study. Nephrol Dial Transplant 1994; 9: 1611-1615.
63. Fabrizi F, Marcelli D, Bacchini G, Guarnori I, Erba G et al.: Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease. Nephrol Dial Transplant 1994; 9: 780-784.
64. Fabrizi F, Lunghi G, Marai P, Marcelli D, Guarnori I et al.: Virological and histological features of hepatitis C virus (HCV) infection in kidney transplant recipients. Nephrol Dial Transplant 1996; 11: 159-164.
65. Uematsu T, Hanada S, Saito T, Otsuka M, Komidori K et al.: Adult T cell leukemia in hemodialysis patients from the Kagoshima district, an area, in which human T cell leukemia virus type I is highly endemic. Nephron 1989; 51: 257-260.
66. Shousha S, Arnaout AH, Abbas SH, Parkins RA: Antral Helicobacter pylori in patients with chronic renal failure. J Clin Pathol 1990; 43: 397-399.
67. Penn I: Primary kidney tumors before and after renal transplantation. Transplantation 1995; 59: 480-485.
68. Mellemgaard A, Moller H, Olsen J, Jensen OM: Diuretics may increase risk of renal-cell carcinoma. Cancer Causes Control 1992; 3: 309-312.
69. Mellemgaard A, Niwa S, Mehl ES, Engholm G, McLaughlin JK et al.: Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol 1994; 23: 923-930.
70. Weinmann S, Glass AG, Weiss NS, Psaty BM, Siscovick DS White E: Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol 1994; 140: 792-804.
71. McLaughlin JK, Chow WH, Mandel JS, Mellemgaard A, Mccredie M et al.: International renal-cell cancer study. 8. Role of diuretics, other antihypertensive medications and hypertension. Int J Cancer 1995; 63: 216-221.
72. Pahor M, Guralnik JM, Ferrucci L, Corti M-C, Salive ME et al.: Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-497.
73. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P et al.: Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-699.
74. Trump BF, Jones TW, Elliget KA, Smith MW, Phelps PC et al.: Relation between toxicity and carcinogenesis in the kidney: an heuristic hypothesis. Renal Failure 1990; 12: 183-191.
75. Trump BF, Berezesky IK: Calcium-mediated cell injury and ceil death. FASEB J 1995; 9: 219-228.
76. Whitfield JF: Calcium signals and cancer. Crit Rev Oncog 1992; 3: 55-90.
77. 2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminphen. FASEB J 1993; 7: 453-463.
78. Yanagisawa H, Manabe S, Kanai Y, Wada O: Carcinogenic glutamic acid pyrolysis product in the dialysate of uremic patients treated by continuous ambulatory peritoneal dialysis. Clin Nephrol 1988; 30: 73-78.
79. Yanagisawa H, Wada O: Significance of IQ-type heterocyclic amines, dietary carcinogens in the plasma of patients with uremia just before induction of hemodialysis treatment. Nephron 1989; 52: 6-10.
80. Manabe S, Suzuki M, Kusano E, Wada O, Asano Y: Elevation of levels of carcinogenic tryptophan pyrolysis products in plasma and red blood cells of patients with uremia. Clin Nephrol 1992; 37: 28-33.
81. Dunn SR, Simenhoff ML, Lele PS, Goyal S, Pensabene JW et al.: N-nitrosodimethylamine blood levels in patients with chronic renal failure: modulation of levels by ethanol and ascorbic acid. J Natl Cancer Inst 1990; 82: 783-787.
82. Simenhoff ML, Dunn SR, Zollner GP, Fitzpatrick MED, Emery SM et al.: Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab 1996; 22: 92-96.
83. Perna AF, Ingrosso D, De-Santo NG, Galletti P, Zappia V: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995; 47: 247-253.
84. Galletti P, Ingrosso D, Manna C, Clemente G, Zappia V: Protein damage and methylation-mediated repair in the erythrocyte. Biochem J 1995; 306: 313-325.
85. Perna A, Ingrosso D, Galletti P, Zappia V, De Santo NG: Membrane protein damage and methylation reactions in chronic renal failure. Kidney Int 1996; 30: 358-366.
86. Wainfan E, Poirier LA: Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res 1992; 52: 2071S-2077S.
87. Laird PW, Jaenisch R: DNA methylation and cancer. Hum Mol Genet 1994; 1487-1495.
88. Dizik M, Christman JK, Wainfan E: Alterations in expression and methylation of specific genes in livers of rats fed a cancer promoting methyl-deficient diet. Carcinogenesis 1991; 12: 1307-1312.
89. Pogribny IP, Basnakian AG, Miller BJ, Lopatina NG, Poirier LA et al.: Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer 1995; 55: 2711-2717.
90. Craddock PR, Fehr J, Dalmasso AP, Brigham KL, Jacob HS: Hemodialysis leukopenia: pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59: 879-888.
91. Heidland A, Hörl WH, Heller N, Heine H, Neumann S et al.: Proteolytic enzymes and catabolism: enhanced release of granulocyte proteinases in uremic intoxication and during hemodialysis. Kidney Int 1983; 24: S27-S36.
92. Hörl WH, Riegel W, Steinhauer HB, Wanner C, Schollmeyer P et al.: Plasma levels of main granulocyte components during hemodialysis. In: Koch M, Streicher E (Hrsg): Biological reactions within the extracorporal circuit during hemodialysis. Contributions to nephrology 59. Basel: Karger, 1987: 35-43.
93. Dinarello CA, Koch KM, Shaldon S: Interleukin-1 and its relevance in patients with hemodialysis. Kidney Int 1988; 33: S21-S26.
94. Stefoni S, Feliciangeli G, Costa AN, Coli L, Cianciolo G et al.: Approach to dialysis biocompatibility: evaluation through in vivo investigation of lymphocyte biology. In: Bonimini V (Hrsg): Evolution in dialysis adequacy. Basel: Karger, 1993: 65-75.
95. Bloembergen WE, Port FK, Hakim RM, Stannard D, Wolfe RA et al.: The relationship of dialysis membrane and cause-specific mortality in chronic hemodialysis patients. Renal Data System and University of Michigan. J Am Soc Nephrol 1995; 6: 521A.
96. Vamvakas S, Bahner U, Becker P, Steinle A, Götz R et al.: Impairment of DNA repair in the course of long-term hemodialysis and under cyclosporine immunosuppression after renal transplantation. Transplant Proc 1996; 28: 3468-3473.
97. Zevin D, Malachi T, Gafter U, Friedman J, Levi J: Impaired DNA repair in patients with end-stage renal disease and its improvement with hemodialysis. Miner Electrolyte Metab 1991; 17: 303-306.
98. Malachi T, Zevin D, Gafter U, Chagnac A, Slor H et al.: DNA repair and recovery of RNA synthesis in uremic patients. Kidney Int 1993; 44: 385-389.
99. Massry SG: Parathyroid hormone: a uremic toxin. In: Ringoir S, Vanholder R, Massry SG (Hrsg): Uremic toxins. New York: Plenum press, 1987: 1-17.
100. Malachi T, Gafter U, Weinstein T, Breitbart H: Elevated cellular calcium and impaired DNA repair ability in uremic patients. J Am Soc Nephrol 1995; 6: 583A.